'Responsibly' priced Invokana debuts in India

Janssen has launched its selective sodium glucose co-transporter 2 (SGLT2) inhibitor Invokana (canagliflozin) for type 2 diabetes in India – sticking with its "commitment" of offering India-specific pricing for its products as far as possible.